HHS is considering whether unmodified islet cells from deceased donors should be regulated as organs for transplant or as biological products for type 1 diabetes. The policy question, framed as a reclassification debate, affects oversight pathways, risk management and the manufacturing-like expectations for cellular products. The initiative comes as the field continues to evolve from conventional transplants toward more standardized, scalable islet preparation workflows. Changing classification would influence how sponsors design studies, submit documentation, and handle post-market responsibilities. For biotech companies in islet transplantation and next-generation cell therapies, the potential regulatory shift is a direct variable in time-to-clinic and long-term commercial planning.